Last updated on January 2019

Efficacy and Safety of 0.1% Timolol Gel in Healing Split-thickness Skin Grafts Donor and Receiving Sites


Brief description of study

The use of topical beta-blockers, such as 0.1% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 72 patients who have their skin cancer surgically removed and require a split-thickness skin graft to close their surgical wound. The objective of this randomized, open-label safety study is to determine the safety and efficacy of 0.1% timolol in promoting wound healing in split-thickness skin graft donor and receiving sites.

Detailed Study Description

The standard therapy for split-thickness skin graft (STSG)

All other adverse reactions will be analyzed and reported, if applicable.

Clinical Study Identifier: NCT03452072

Find a site near you

Start Over